Department of Health
An Roinn Sláinte
Männystrie O Poustie
www.health-ni.gov.uk

For Action: Assistant Director Integrated Care, Head of Pharmacy and Medicines Management, Strategic Planning and Performance Group & BSO
Heads of Pharmacy and Medicines Management of HSC Trusts
Regulation Quality Improvement Authority

From: Chief Pharmaceutical Officer
Mrs Cathy Harrison
Castle Buildings
Upper Newtownards Road
Belfast BT4 3SQ

Telephone: 028 90 523219
Facsimile: 028 90 522335

E-Mail: cathy.harrison@health-ni.gov.uk

Our Ref: PHC/10/2023
Date: 16 March 2023

M E D I C I N E S N O T I F I C A T I O N

CLASS 4 MEDICINES DEFECT INFORMATION

Caution in Use
Distribute to Pharmacy / Wholesaler Level

Dear Healthcare Professional,

Macarthys Laboratories t/a Martindale Pharma (an Ethypharm Group Company)

Venlafaxine XL 150mg prolonged-release tablets **PL01883/0340**

SNOMED Code 41468211000001100

Batch Number	Expiry Date	Pack Size	First Distributed
LC70019	08 2025	30	10/02/2023
LC70020	08 2025	30	13/02/2023

Active Pharmaceutical Ingredient: venlafaxine hydrochloride

Venlafaxine XL 225mg prolonged-release tablets **PL01883/0341**

SNOMED Code 41482811000001100

Batch Number	Expiry Date	Pack Size	First Distributed
LC70053	08 2025	30	09/02/2023
LC70054	08 2025	30	Not yet distributed

Active Pharmaceutical Ingredient: venlafaxine hydrochloride

Venlafaxine XL 300mg prolonged-release tablets **PL01883/0363**

SNOMED Code 37997111000001100

Batch Number	Expiry Date	Pack Size	First Distributed
LC69693	07 2024	30	Not yet distributed
LC69699	07 2024	30	Not yet distributed
LC69701	07 2024	30	Not yet distributed

Active Pharmaceutical Ingredient: venlafaxine hydrochloride

Brief description of the problem:
Additional to the batches included in the previous Class 4 Medicines Notification (reference PHC/50/2022) Martindale Pharma has made the MHRA aware that the GTIN in the 2D barcode and the printed variable data represents the branded version of the product (Venlalic® XL prolonged-release tablets). It should instead reflect the generic name: Venlafaxine XL prolonged-release tablets. The code under the pre-printed barcode is correct.

Advice for healthcare professionals:
There is no risk to product quality as a result of this issue, therefore the affected batches are not being recalled. In November 2022, Martindale Pharma had confirmed that no other batches were impacted. However, due to manufacturing issues, additional batches are now impacted by the same issue, including some batches that have not been distributed yet. Due to the market share of this product and consideration of the overall supply position, the batches above are not being recalled and continued distribution of the batches listed in the notification will take place.

Healthcare professionals are advised to exercise caution when dispensing the products. Additional precautions should be considered by wholesalers and pharmacies using automated inventory systems to dispense the affected batch within the pharmacy or wholesale facility.

Advice for patients:
This notification relates to a barcode error on the outer packaging of the product. The medicine itself is not affected and patients do not need to take any action.

Further Information:
For further information, medical enquiries and stock information, contact:
Licensed@ethypharm.com

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. RQIA should bring this information to the attention of private hospitals/clinics registered with them and any other relevant care facilities.

The Business Services Organisation is asked to bring this information to the attention of Community Pharmacists and General Medical Practitioners directly.

Yours sincerely

Mrs Cathy Harrison
Chief Pharmaceutical Officer